Company gains oncology-related tests and biomarkers for prognosis and treatment-response prediction.
bioMérieux acquired AviaraDx for $60 million expanding its portfolio of infectious disease molecular diagnostics to include tests that aid cancer management. The firm also gains AviaraDx’ CLIA-certified lab.
AviaraDx will operate as an independent legal entity called bioTheranostics. The company has traditionally been focused on R&D with 19 employees and a limited sales team. bioMérieux reports that AviaraDx has had restricted sales and is projected to lose approximately $8 million this year. bioTheranostics is also predicted to have lower sales until 2012 and break even around that year.
AviaraDx’ diagnostic tests are used to classify cancers on a molecular level to assist with prognosis. The company also has reportedly validated cancer biomarkers and capabilities in gene-expression profiling in tissues.
Aviara CancerTYPE ID® provides cancer classification, especially for patients diagnosed with metastatic cancer where the origin is uncertain or unknown. Aviara Breast Cancer Index is used to evaluate two Aviara markers (H/I and MGI) for risk prognosis and treatment-response prediction for chemo and hormonal therapy.
